SIM-0610

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameSIM-0610
Drug Alias NameSIM-0610SIM0610
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Hepatocyte growth factor receptorDNA topoisomerase I inhibitors
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptorDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSimcere Pharmaceutical Group Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Xianwei Pharmaceutical Technology Co LtdSimcere Pharmaceutical Group LtdJiangsu Simcere Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A